Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Launched by PFIZER · Jul 16, 2013
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Only subjects previously participating in two specific studies are eligible to enroll into this study. Enrollment is not open to subjects if not previously enrolled in studies B1871006 or B1871008.
- Exclusion Criteria:
- • All subjects are excluded unless previously participating in studies B1871006 or B1871008.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sioux City, Iowa, United States
Adelaide, South Australia, Australia
Madrid, , Spain
Atlanta, Georgia, United States
Singapore, , Singapore
Atlanta, Georgia, United States
Poitiers, , France
Houston, Texas, United States
Vancouver, British Columbia, Canada
Atlanta, Georgia, United States
Madrid, , Spain
Houston, Texas, United States
Madrid, , Spain
Toledo, , Spain
Beijing, , China
Amsterdam, , Netherlands
Indianapolis, Indiana, United States
Hawthorne, New York, United States
Valencia, , Spain
Hershey, Pennsylvania, United States
Beijing, Beijing, China
Barcelona, , Spain
Beijing, , China
Chai Wan, , Hong Kong
Herston, Queensland, Australia
Suita City, Osaka, Japan
Gdansk, , Poland
La Plata, Buenos Aires, Argentina
Budapest, , Hungary
Akita City, Akita, Japan
Gdansk, , Poland
Krakow, , Poland
Lublin, , Poland
Poitiers Cedex, , France
Newcastle Upon Tyne, , United Kingdom
Ankara, , Turkey
Toronto, Ontario, Canada
Orlando, Florida, United States
Gdańsk, , Poland
Hangzhou, Zhejiang, China
Montreal, Quebec, Canada
Tokyo, , Japan
Seoul, , Korea, Republic Of
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Bethesda, Maryland, United States
Cd. Autonoma De Buenos Aires, Buenos Aires, Argentina
Corrientes, , Argentina
Charleroi, , Belgium
Campinas, Sp, Brazil
Santo Andre, Sp, Brazil
Edmonton, Alberta, Canada
Renaca, V Region, Chile
Renaca, V Region, Chile
Shanghai, , China
Tianjin, , China
Bogota, Cundinamarca, Colombia
Helsinki, , Finland
Caen Cedex 9, , France
Nantes Cedex 1, , France
Strasbourg, , France
Shatin, New Territories, , Hong Kong
Kaposvar, , Hungary
Vellore, Tamil Nadu, India
Bologna, Bo, Italy
Monza, Monza And Brianza, Italy
Orbassano, To, Italy
Roma, , Italy
Toyohashi, Aichi, Japan
Fukuoka Shi, Fukuoka, Japan
Kanazawa Shi, Ishikawa, Japan
Osakasayama City, Osaka, Japan
Hamamatsu Shi, Shizuoka, Japan
Riga, , Latvia
Groningen, , Netherlands
Lima, , Peru
Ekaterinburg, Sverdlovsk Region, Russian Federation
Moscow, , Russian Federation
Rostov On Don, , Russian Federation
Rostov On Don, , Russian Federation
Saint Petersburg, , Russian Federation
Saint Petersburg, , Russian Federation
Saint Petersburg, , Russian Federation
Samara, , Russian Federation
Soweto, Gauteng, South Africa
Madrid, , Spain
Bangkok, , Thailand
Gaziantep, Sehit Kamil, Turkey
Cherkasy, , Ukraine
Dnipropetrovsk, , Ukraine
Kyiv, , Ukraine
Kyiv, , Ukraine
Lviv, , Ukraine
Nottinhgam, , United Kingdom
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials